Vital Therapies Announces Management Addition; Enrollment in VTI-208 Phase 3 Trial Now 75 Percent Complete
08 sept. 2014 08h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, is...
Vital Therapies Announces Second Quarter 2014 Financial Results and Provides Update on Operations and Upcoming Conference Presentations
06 août 2014 16h34 HE
|
Vital Therapies, Inc.
SAN DIEGO, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute liver failure,...
Vital Therapies Announces Poster Presentation at the 2014 World Transplant Congress
28 juil. 2014 16h15 HE
|
Vital Therapies, Inc.
SAN DIEGO, July 28, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure,...
Vital Therapies Reports on Clinical Trial Progress and EU Regulatory Advice
09 juil. 2014 05h30 HE
|
Vital Therapies, Inc.
SAN DIEGO, July 9, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, is...